Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC

Inclusion Criteria: * Histologically proven squamous cell carcinoma. * All lesions are located in the thoracic esophagus. * Clinical stages IIB and III (excluding T4) based on the 7th UICC-TNM classification. * 20-75 years old. * ECOG performance status of 0 or 1. * Measurable lesions not required. * No prior therapy against esophageal cancer except for complete resection by endoscopic mucosal resection/endoscopic submucosal dissection with either pM1/M2 disease or pM3 disease without vascular infiltration. * No prior chemotherapy, radiotherapy or hormonal therapy against any cancers * Adequate organ function. * Written informed consent. Exclusion Criteria: * Synchronous or metachronous double cancers, except for intramucosal tumor curatively resected by local therapy. * Active infection requiring systemic therapy * Positive hepatitis B surface antigen and hepatitis B core antigen or human immunodeficiency virus antibody.(only positive hepatitis B surface antigen should receive anti-virus treatment during study) * Pregnant or lactating women or women of childbearing potential. * Patients requiring systemic steroid medication. * Iodine hypersensitivity. * Psychiatric disease. * Hypersensitivity for CremophorEL. * Poorly controlled diabetes. * Severe emphysema or pulmonary fibrosis. * Poorly controlled hypertension. * Unstable angina within 3 weeks or with a history of myocardial infarction within 6 months.